FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 366 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... July 22, 2020 Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 Study Identifies Potential Drug Target to Prevent Some Liver Cancers February 4, 2022 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 Load more HOT NEWS SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer How Wartime Violence Against Women Is Hurting Millions Worldwide Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant Working to Make Cancer Clinical Trials More Inclusive: A Q&A With...
